輝立:予三生製藥(1530.HK)目標價14港元
輝立予三生製藥(1530.HK)目標價14港元。
輝立發佈報告稱,三生製藥旗下非全資附屬公司三生國健將於2020年7月13日進行普通股的首次公開發售,並預期三生國健的普通股將於7月22日開始於科創板上市及買賣。有關分拆將量化三生國健股權的市場價格,為三生國健提供新的資金來源,提升三生製藥及三生國健的企業及品牌知名度,提升企業管治,吸引人才加入三生國健及提升三生國健的標準、能力及專業知識,有助於三生國健及三生製藥更專注於發展其各自的業務及進行策略規劃。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.